Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enfortumab Vedotin Plus Pembrolizumab in Variant Histology Bladder Cancer
NCT05756569Phase 2Recruiting
- Sponsor
- Emory University
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and pembrolizumab in bladder cancer, sponsored by Emory University. Primary endpoint: Overall Response Rate up to 2 years. Started Sep 2023; status: recruiting.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05756569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756569.